A twist in the science of how people form their political identities
A new, billion-dollar pharmaceutical to treat peanut allergies is up for approval. It’s simply peanut flour.
As a cancer patient, she had received cord-blood cells from an anonymous donor. The DNA from those cells led her to him.
In the latest Democratic presidential debate, the candidates stopped being polite and started getting real.
A national ban on flavored e-cigarettes is coming.
Lead-tainted drinking water is not only a problem in Flint and Newark.
For decades, a landmark brain study fed speculation about whether we control our own actions. It seems to have made a classic mistake.
Why the end of fertility doesn’t mark the start of decline—and may even help explain our success as a species.
Ongoing FDA investigations and a spate of hospitalizations show that “safer than cigarettes” does not mean safe.
Most boycotts fail. Why does this one seem to be working?
There’s a reason the return of retro trends bothers so many people.
Urinary-tract infections were once easy to cure. Then they started becoming resistant to antibiotics.
The “Jamaica study” has garnered more attention online than 99 percent of scientific research.
Sam faces a dilemma as he comes of age in the shadow of Britain's largest power plant.
It’s here, and it’s inadequate.
As Americans sink under medical expenses, debt collectors go to great—and sometimes strange—lengths to collect.
Could AI teach doctors when to stop talking?
Here’s to giving up.
I spent $1,279 of The Atlantic’s money on creams, crystals, and a vibrator from Gwyneth Paltrow’s wellness empire. Things got weird.
The president told the VA to purchase a large amount of a controversial new nasal spray. The agency says it will consider incorporating the drug after it has more data.
A number of surprising factors may be contributing to the modern obesity epidemic.